[1]
|
Ramael, S., Daoust, A., Otoul, C., et al. (2006) Levetiracetam intravenous infusion: A randomized, placebo- controlled safety and pharmacokinetic study. Epilepsia, 47, 1128-1135. doi:10.1111/j.1528-1167.2006.00586.x
|
[2]
|
Lyseng-Williamson, K.A. (2011) Levetiracetam: A review of its use in epilepsy. Drugs, 71, 489-514.
|
[3]
|
Walker, M.C. and Patsalos, P.N. (1995) Clinical pharma- cokinetics of new antiepileptic drugs. Pharmacology & Therapeutics, 67, 351-384.
doi:10.1016/0163-7258(95)00021-6
|
[4]
|
Brockmoller, J., Thomsen, T., Wittstock, M., Coupez, R., Lochs, H. and Roots, I. (2005) Pharmacokinetics of levetiracetam in patients with moderate to severe liver cirrhosis (child-pugh classes A, B, and C): Characterization by dynamic liver function tests. Clinical Pharmacology & Therapeutics, 77, 529-541.
|
[5]
|
Droz-Perroteau, C., et al. (2010) Eulev cohort study rates of and factors associated with continuation of levetiracetam after 1 year. Beer Judge Certification Program, 77, 121-127.
|
[6]
|
Tan, T.C., de Boer, B.W. and Mitchell, A., et al. (2008) Levetiracetam as a possible cause of fulminant liver fail- ure. Neurology, 71, 685-686.
doi:10.1212/01.wnl.0000324604.11657.c6
|
[7]
|
Skopp, G., Schmitt, H.P. and Pedal, I. (2006) Fulminant liver failure in a patient on carbamazepine and levetiracetam associated with status epilepticus. Archiv für Kriminologie, 217, 161-175.
|
[8]
|
Feeney, D.M. and Walker, A.E. (1979) The prediction of posttraumatic epilepsy. A mathematical approach. Archives of Neurology, 36, 8-12.
doi:10.1001/archneur.1979.00500370038005
|
[9]
|
Naranjo, C.A., Busto, U., Sellers, E.M., Sandor, P., Ruiz, I., Roberst, E.A., et al. (1981) A method for estimating the probability of adverse drug reactions. Clinical Phar- macology & Therapeutics, 30, 239-245.
doi:10.1038/clpt.1981.154
|
[10]
|
Hill, A.B. (1965) The environment and disease: Association or causation? Proceedings of the Royal Society of Medicine, 58, 295-300.
|
[11]
|
Lee, W.M. (2003) Drug-induced hepatotoxicity. The New England Journal of Medicine, 349, 474-485.
doi:10.1056/NEJMra021844
|
[12]
|
Navarro, V.J. and Senior, J.R. (2006) Drug-related heaptotoxicity. The New England Journal of Medicine, 354, 731-739. doi:10.1056/NEJMra052270
|
[13]
|
Alvestad, S., Lydersen, S. and Brodtkorb, E. (2008) Cross-reactivity pattern of rash from current antiepileptic drugs. Epilepsy Research, 80, 194-200.
doi:10.1016/j.eplepsyres.2008.04.003
|
[14]
|
Ahmed, S.N. and Siddiqi, Z.A. (2006) Antiepileptic drugs and liver disease. Seizure, 15, 156-164.
doi:10.1016/j.seizure.2005.12.009
|